609788-04-7

Basic information

• Product Name: Carbamic acid, [(1R,3R)-3-aminocyclohexyl]-, 1,1-dimethylethyl ester, rel- (9CI)
• Synonyms: Carbamic acid, [(1R,3R)-3-aminocyclohexyl]-, 1,1-dimethylethyl ester, rel- (9CI);tert-butyl [trans-3-aminocyclohexyl]carbamate;tert-butyl rac-[(1R,3R)-3-aminocyclohexyl]carbamate
• CAS NO: 609788-04-7
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.30458
• Product Categories: N-BOC
• Mol File: 609788-04-7.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 322.1±31.0 °C(Predicted)
• Appearance: /
• Density: 1.02±0.1 g/cm3(Predicted)
• PKA: 12.40±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1R,3R)-3-aminocyclohexyl]-, 1,1-dimethylethyl ester, rel- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R,3R)-3-aminocyclohexyl]-, 1,1-dimethylethyl ester, rel- (9CI)(609788-04-7)
• EPA Substance Registry System: Carbamic acid, [(1R,3R)-3-aminocyclohexyl]-, 1,1-dimethylethyl ester, rel- (9CI)(609788-04-7)

Safety Data

• Hazardous Substances Data: 609788-04-7(Hazardous Substances Data)

Upstream product

• 53084-60-9 ethyl (1R,3S)-3-aminocyclohexanecarboxylate 
• 227783-08-6 (1S,3R)-3-ethoxycarbonylcyclohexane-1-carboxylic acid 
• 1261225-49-3 [3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 1259278-09-5 ethyl (1R,3S)-3-benzyloxycarbonylaminocyclohexane-1-carboxylate 
• 1259278-11-9 benzyl N-[(1S,3R)-3-carbamoylcyclohexyl]carbamate 
• 1259278-12-0 benzyl N-[(1S,3R)-3-aminocyclohexyl]carbamate 
• 1261225-48-2 [3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 34619-03-9 tert-butyldicarbonate 
• 3385-21-5 1,3-diaminocyclohexane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 498532-32-4 cis-1,3-cyclohexanediamine dihydrochloride 
• 347186-01-0 N-(3-aminocyclohexyl)(t-butoxy)carboxamide 
• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 

Relevant articles and documents

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

CYCLOALKANE-1,3-DIAMINE DERIVATIVE

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.